Dr. Eric J. Grigsby, M.D.
Pain Medicine (Pain Medicine Physician)
- Medicare participating
At a glance
- Medical school
- Boston University School of Medicine (1984)
- Years since graduation
- 42
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 87
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1984Medical school: Boston University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pain Medicine Physician primary
CA license G648480
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Adventist Health Clearlake Clearlake, CA
- Providence Queen of the Valley Medical Center Napa, CA
- Adventist Health St Helena Saint Helena, CA
Medical groups
- Spectrumcare Rehabilitation Medical (3 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 87
- Services billed
- 534
- Patients’ average age
- 69
| Service | Times | Patients |
|---|---|---|
| Unclassified drugs | 114 | 64 |
| Electronic analysis reprogramming and refill of spinal canal drug infusion pump by physician | 82 | 53 |
| Established patient office or other outpatient visit, 20-29 minutes | 67 | 44 |
| Chronic pain management and treatment, monthly bundle including, diagnosis; assessment and monitoring; administration of a validated pain rating scale or tool; the development, implementation, revision, and/or maintenance of a person-centered care plan tha | 62 | 55 |
| Ultrasonic guidance for needle placement | 60 | 52 |
| Testing for presence of drug, by chemistry analyzers | 57 | 46 |
| Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | 49 | 39 |
| Established patient office or other outpatient visit, 30-39 minutes | 33 | 29 |
| 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 22 | 14 |
| Aspiration of cerebrospinal fluid and injection in shunt tubing or reservoir | 12 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Payments from drug and device companies
In 2025, 1 companies reported 2 payments worth $53.36 in total to this clinician.
| Medtronic, Inc. | $53.36 |
|---|
| Food and Beverage | $53.36 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 10 industry-funded studies in 2025, from 4 companies. The companies reported $396,819 in research payments for these studies, mostly to the institutions running them.
- A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of HZN-1116 in Participants With Sjgren's Syndrome
Amgen Inc. - A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)
Eli Lilly and Company · Active, not recruiting · NCT05026866 - PSR-TDD
Medtronic, Inc. - A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of HZN-1116 in Participants With Sjgrens Syndrome
Amgen Inc. - A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimers Disease (Targe…
E.r. Squibb & Sons, L.l.c. - P2 HZN-1116-201 Sjogren's Syndrome (SS)
Amgen Inc. - PSR-PSTM
Medtronic, Inc. - A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
Eli Lilly and Company · Active, not recruiting · NCT04437511 - A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity
Amgen Inc. - Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease
E.r. Squibb & Sons, L.l.c. · Active, not recruiting · NCT06268886
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.